138 research outputs found
Classificazione della marginalitĂ dei piccoli comuni del Piemonte 2009
Contributi di ricerca ; n.235/2009- Indice #6- Introduzione #8- I piccoli comuni del Piemonte #10- MarginalitĂ socioeconomica #18- I risultati dell'analisi #30- Allegati #4
Classificazione della marginalitĂ dei piccoli comuni del Piemonte 2008
Strumentires ; 12- Indice #3- Introduzione #9- I piccoli comuni del Piemonte #11- La marginalitĂ socioeconomica #16- I risultati dell'analisi #32- Appendici #4
Da margine a centro. Verso un modello di governance per Corona Verde
Da margine a centro. Verso un modello di governance per Corona Verde- Indice #6- Parte 1. Obiettivi e presupposti teorici #12- Parte 2. Le analisi e il confronto con gli stakeholders #26- Parte 3. Dalle analisi ai modelli di governance #50- Parte 4. Le proposte operative #5
Radioresistance in rhabdomyosarcomas: Much more than a question of dose
Management of rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children, frequently accounting the genitourinary tract is complex and requires a multimodal therapy. In particular, as a consequence of the advancement in dose conformity technology, radiation therapy (RT) has now become the standard therapeutic option for patients with RMS. In the clinical practice, dose and timing of RT are adjusted on the basis of patients' risk stratification to reduce late toxicity and side effects on normal tissues. However, despite the substantial improvement in cure rates, local failure and recurrence frequently occur. In this review, we summarize the general principles of the treatment of RMS, focusing on RT, and the main molecular pathways and specific proteins involved into radioresistance in RMS tumors. Specifically, we focused on DNA damage/repair, reactive oxygen species, cancer stem cells, and epigenetic modifications that have been reported in the context of RMS neoplasia in both in vitro and in vivo studies. The precise elucidation of the radioresistance-related molecular mechanisms is of pivotal importance to set up new more effective and tolerable combined therapeutic approaches that can radiosensitize cancer cells to finally ameliorate the overall survival of patients with RMS, especially for the most aggressive subtypes
Cinque anni insieme
Il contributo, che costituisce l'editoriale della rivista EyesReg per l'anno 2016, riepiloga i temi piĂč interessanti e gli elementi piĂč significativi dell'attivitĂ della rivista nel corso dell'ultimo ann
MS-275 (Entinostat) Promotes Radio-sensitivity in PAX3-FOXO1 Rhabdomyosarcoma cells
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. About 25% of RMS expresses fusion oncoproteins such as PAX3/PAX7âFOXO1 (fusionâpositive, FP) while fusionânegative (FN)âRMS harbors RAS mutations. Radiotherapy (RT) plays a crucial role in local
control but metastatic RMS is often radioâresistant. HDAC inhibitors (HDACi) radioâsensitize different cancer cells types. Thus, we evaluated MSâ275 (Entinostat), a Class I and IV HDACi, in combination with RT on RMS cells in vitro and in vivo. MSâ275 reversibly hampered cell survival
in vitro in FNâRMS RD (RASmut) and irreversibly in FPâRMS RH30 cell lines downâregulating cyclin A, B, and D1, upâregulating p21 and p27 and reducing ERKs activity, and câMyc expression in RD and PI3K/Akt/mTOR activity and NâMyc expression in RH30 cells. Further, MSâ275 and RT
combination reduced colony formation ability of RH30 cells. In both cell lines, coâtreatment increased DNA damage repair inhibition and reactive oxygen species formation, downâregulated NRF2, SOD, CAT and GPx4 antiâoxidant genes and improved RT ability to induce G2 growth arrest.
MSâ275 inhibited in vivo growth of RH30 cells and completely prevented the growth of RTâunresponsive RH30 xenografts when combined with radiation. Thus, MSâ275 could be considered as a radioâsensitizing agent for the treatment of intrinsically radioâresistant PAX3âFOXO1 RMS
- âŠ